Impact of tofacitinib treatment on human B-cells in vitro and in vivo

• Published in: Journal of autoimmunity Vol. 77; pp. 55 - 66
• Main Authors: Rizzi, Marta, Lorenzetti, Raquel, Fischer, Kathleen, Staniek, Julian, Janowska, Iga, Troilo, Arianna, Strohmeier, Valentina, Erlacher, Miriam, Kunze, Mirjam, Bannert, Bettina, Kyburz, Diego, Voll, Reinhard E, Venhoff, Nils, Thiel, Jens
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2017
• Subjects: Allergy and Immunology; Antibody Formation - drug effects; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - immunology; Arthritis, Rheumatoid - metabolism; B-lymphocytes; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; B-Lymphocytes - metabolism; Cells, Cultured; Cytidine Deaminase - metabolism; Humans; Immune modulation; Immunoglobulin Class Switching - drug effects; Immunomodulation; Interleukin Receptor Common gamma Subunit - metabolism; JAK inhibitors; Lymphocyte Activation - drug effects; Lymphocyte Activation - immunology; Lymphocyte Count; Piperidines - pharmacology; Piperidines - therapeutic use; Plasma Cells - drug effects; Plasma Cells - immunology; Plasma Cells - metabolism; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Pyrroles - pharmacology; Pyrroles - therapeutic use; Rheumatoid arthritis; Signal Transduction - drug effects; Tofacitinib; tsDMARDs; B-lymphocytes; tsDMARDs; Tofacitinib; Rheumatoid arthritis; Immune modulation; JAK inhibitors

Abstract B-cells are pivotal to the pathogenesis of rheumatoid arthritis and tofacitinib, a JAK inhibitor, is effective and safe in its treatment. Tofacitinib interferes with signal transduction via cytokine receptors using the common γ-chain. Despite extensive data on T-lymphocytes, the impact of t...